⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299338 | 0.59 | — | — | |
| SCHEMBL377549 | 0.59 | — | — | |
| Hydrochloric Acid SCHEMBL28908158 | 0.56 | — | — | |
| SCHEMBL19421998 | 0.56 | — | — | |
| SCHEMBL30805669 | 0.56 | — | — | |
| SCHEMBL25195373 | 0.56 | — | — | |
| Water SCHEMBL28842263 | 0.56 | — | — | |
| SCHEMBL14581047 | 0.56 | — | — | |
| SCHEMBL7648823 | 0.56 | — | — | |
| SCHEMBL14864352 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | claimed |
| US-5776718-A | Reversible protease inhibitors | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-07-07 | — | — | US | claimed |
| EP-0817778-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030353-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-10-03 | — | — | WO | claimed |
| US-3978078-A | Process for the preparation of ampicillin | RHONE-POULENC S.A. (FR) | 1976-08-31 | — | — | US | claimed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-115298192-A | 4' -O-methylene phosphonate nucleic acids and analogs thereof | 迪克纳制药公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-107709288-A | Phosphamide derivative and preparation method and application thereof | 四川海思科制药有限公司 | 2018-02-16 | — | — | CN | disclosed |
| US-6521432-B1 | Antigen with difluoroketone, phosphoramidate, or phosphonate epitope capable of eliciting biocatalytic antibody | IGEN INTERNATIONAL, INC. | 2003-02-18 | — | — | US | disclosed |
| US-5916721-A | BINDER RESIN, AZOMETHINE DYE | KONICA CORPORATION (JP) | 1999-06-29 | — | — | US | disclosed |
| US-5776718-A | Reversible protease inhibitors | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0817778-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030353-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0476059-B1 | METHODS FOR ENHANCING THE RATE OF MODIFICATION OF METASTABLE BONDS | IGEN INC (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0569487-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0569487-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1993-11-18 | — | — | EP | disclosed |
| US-3978078-A | Process for the preparation of ampicillin | RHONE-POULENC S.A. (FR) | 1976-08-31 | — | — | US | disclosed |